ScientiaCME

ScientiaCME CME Courses

Credits: 1.0 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: May 12, 2016
Expiration Date: May 12, 2018
Summary:

Acute lymphoblastic leukemia (ALL) is one of a group of malignancies caused by cytogenetic DNA mutations of developing hematopoietic stem cell precursors and mostly common to children with peak incidence at 2-5 years of age. Although approximately 80% of ALL cases present in children, they also occur in adults.  The symptoms of ALL are non-specific and similar to those of acute myelogenous leukemia (AML), which patients usually have 1-3 months of complaints.

By the end of the session the participant will be able to:

  • Summarize the most impactful findings presented at ASH 2015 relating to ALL and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, PDF, Online Download, Interactive Online
Price: Free
Release Date: October 19, 2017
Expiration Date: October 19, 2019
Summary:

Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.

By the end of the session the participant will be able to:

  • Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
  • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
  • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
  • Describe the challenges and barriers to care associated with treating patients with mCRC
Credits: 1 (AMA PRA Category 1)
Format: Interactive Online, Online Streaming Video, PDF
Price: Free
Release Date: November 02, 2017
Expiration Date: November 02, 2019
Summary:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.

By the end of the session the participant will be able to:

  • Recall updates in the staging, prognosis, and diagnosis of MM.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.
Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, Interactive Online
Price: Free
Release Date: October 13, 2017
Expiration Date: October 13, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the epidemiology of AUD and outline current and evolving diagnostic criteria
  • Describe challenges to the successful identification of patients with AUD
  • Identify the treatment modalities currently available for management of AUD and apply them to patient cases using evidence-based medicine
  • Develop strategies for recognizing and improving therapeutic adherence in patients treated for AUD

Alcohol use disorder (AUD), referred to colloquially as alcoholism, is an integration of past terms that have include in past as alcohol dependence or abuse, and may be marked by any one of a number of different symptoms or behaviors that include physical cravings, compulsion, guilt, and frequent consumption over an extended period of time. There are about 7.9 million people in the United States who suffer from the disease, but a fraction – 2.2 million people – seek treatment for it. The number of people who are considered heavy drinkers is about double at somewhere between 15.9 and 17.6 million, and just under a quarter of Americans over age 12 reports having engaged in binge drinking at least once in the last month. Alcohol accounts for over 687,000 emergency department visits by people under age 20 per year, and AUD is estimated to cost $223.5 billion per year. Worldwide, 76.3 million people are estimated to have AUDs, and they account for an annual mortality rate of 1.8 million. AUD is largely undertreated, constituting one gap in care and justifying CME


Credits: 1 (AMA PRA Category 1)
Format: Online Streaming Video, Online Download
Price: Free
Release Date: October 02, 2017
Expiration Date: October 02, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the pathophysiology of chronic idiopathic constipation
  • Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients
  • Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation.
  • Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatment

Target Audience: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation

Credits: 0.75 (CE)
Format: Interactive Online
Price: Free
Release Date: Jan 19, 2018
Expiration Date: Jan 19, 2020
Summary:

This is an online, self online CME self-learning program for therapeutic updates, best practices, and emerging therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly.

By the end of the session the participant will be able to:

  • Describe the pathophysiology of CIDP such that it might inform treatment mechanisms
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of CIDP and apply them to patient cases using evidence-based medicine
  • Modify an existing treatment plan for a specific patient with CIDP to optimize safety and efficacy following non-response to therapy
  • Describe non-pharmacological options to manage CIDP

Credits: 1.25 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: Dec 4, 2017
Expiration Date: Dec 4, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma
Credits: 1 (AMA PRA Category 1)
Format: Online Publication
Price: Free
Release Date: 9/19/2017
Expiration Date: 9/19/2019
Summary:

Learning Objectives:

  • Summarize the most impactful findings presented at ASCO 2017 relating to Metastatic Melanoma and apply them to patient cases, taking into account any relevant barriers to care.
  • Additional objectives to be dictated by clinical content
Credits: 0.75 (CE)
Format: Online Streaming Video, Interactive Online, Multiple Formats
Price: Free
Release Date: Nov 17, 2017
Expiration Date: Nov 17, 2019
Summary:

By the end of the session the participant will be able to:

  • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
  • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
  • Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
  • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case




Credits: 1 (CPE)
Format: Interactive Online, Online Download, Multiple Formats
Price: Free
Release Date: Feb 14, 2018
Expiration Date: Feb 14, 2020
Summary:

By the end of the session the participant will be able to:

  • Describe the underlying pathophysiological and typical clinical features of pediatric GHD as they pertain to therapeutic targets
  • Describe the optimal approach in diagnosing pediatric GHD and apply it to a patient case
  • Given a patient with pediatric GHD, design a pharmacotherapeutic regimen based on his or her clinical presentation
  • Evaluate patient cases during follow-up visits, including during transition therapy to adulthood when relevant, in a manner that optimizes one or more of the following: efficacy, safety, quality of life, or patient education and adherence
  • Describe best practices in tracking response to pediatric GHD therapy
Credits: 1.25 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: Dec 4, 2017
Expiration Date: Dec 4, 2019
Summary:

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma



Credits: 1.0 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Release Date: September 04, 2017
Expiration Date: September 04, 2019
Summary:
This is an online CME self-learning program.

Rheumatoid arthritis (RA) is a systemic autoimmune disorder in which joints, typically those in the hands and feet, become inflamed, swollen, painful, and stiff. Without appropriate treatment, the inflammation may become chronic and cause irreversible destruction of bone and cartilage in the affected joints as well as contribute to the development of clinically important co-morbid conditions with attendant morbidity and mortality. The National Arthritis Data Workgroup estimates that about 1.3 million U.S. adults (0.6% of the adult population) have RA. RA imposes a considerable disease burden. Patients with RA have substantially lower health-related quality of life (QOL) than the general population with lower overall scores for physical and mental health across all age groups.The RA disease burden also is associated with increased health care resource utilization. Notably, RA patients with low QOL are twice as likely to be hospitalized as RA patients with high QOL.

Some have suggested that criteria used for the past two decades are inadequate for addressing the disease burden of RA because by the time a physician detects rheumatoid nodules or radiographic erosion, the optimal time has passed for treatment initiation, representing a gap in care relating to diagnosis of disease. Another potential gap is illustrated by studies in which researchers demonstrated that a systematic, objective approach to therapy with Disease Activity Score-driven therapy yields superior outcomes to routine care.

By the end of the session the participant will be able to:

  • Describe the pathophysiology of RA such that it might inform treatment mechanisms.
  • Describe professional guideline recommendations’ approaches to the diagnosis and treatment of RA and, where applicable, apply them to patient cases
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of RA and apply them to patient cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient with RA to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
  • Describe the challenges and barriers to care associated with treating patients with RA.

Credits: 6.75 (AMA PRA Category 1)
Format: Online Streaming Video
Price: Free
Summary:

Seven lectures from ScientiaCME covering various psychiatry and neuropsychiatry topics, including:

  • ADHD: Therapeutic Updates and Best Practices - released 7/01/2013 (1 CME Hour)
  • Alzheimer Disease andIts Complications: Therapeutic Updates, Best Practices, and Barriers to Care - released 12/21/2015 (1 CME Hour)
  • Bipolar disorder: Therapeutic Updates and Best Practices - released 10/1/2015 (0.75 CME hours)
  • Treatment and Management of Schizophrenia: Barriers to Care, Therapeutic Updates, and Best Practices - released 4/29/2016 (1 CME Hour)
  • Therapeutic Updates and Best Practices in the Treatment of Major Depressive Disorders (MDD) - released 4/12/2016 - (1 CME Hour)
  • Transcendental Medication Techniquest to Treat and Prevent Stress-Related Disorders - released 2/8/2016 (1 CME Hour)
  • Therapeutic Updates, Barriers to Care, and Best Practices in the Treatment of Schizophrenia - released 12/27/2014 (1 CME Hour)

Share This